Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised USD 15 million in a Series B+ financing round. The funds will be used to support bio-business development and product pipeline research and development (R&D). This investment underscores the company’s commitment to advancing its diagnostic solutions and expanding its market presence.
Company Background and Product Highlights
Founded in 2013, GeneBioHealth achieved a significant milestone in 2018 with the marketing approval of its REColon (intestinal cancer stool gene detection) miR-92a detection kit, utilizing the fluorescent RT-PCR method. The company plans to intensify market promotion efforts for this product moving forward. REColon, also authorized in the European Union (EU), demonstrates an 80.45% screening positive predictive value for colorectal cancer and advanced adenoma with polyps. It also achieves screening sensitivity rates of 94.74% for colorectal cancer and 68.33% for advanced adenoma.
Clinical Study and Future Outlook
GeneBioHealth has concluded the first real-world prospective clinical study for colorectal cancer screening, involving 10,000 participants in China. This study highlights the effectiveness and potential impact of REColon in early cancer detection. With the new funding, GeneBioHealth aims to further enhance its product offerings and expand its reach in the global IVD market, particularly in the area of colorectal cancer screening.-Fineline Info & Tech
